Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA
Evidence Based Medicine · 2010-04 · 15 (2) · 40-41
DOI: 10.1136/ebm1034 ↗Kurz gefasst
Kommentar in der Zeitschrift Evidence Based Medicine, online erschienen am 01.05.2010. Verfasst von Wendy A Davis. Beteiligte Einrichtung: University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, PO Box 480, Fremantle WA 6959, Australia. wdavis@meddent.uw…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, PO Box 480, Fremantle WA 6959, Australia. wdavis@meddent.uwa.edu.au
Zitieren
APA
Davis, W. A. (2010). Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA. Evidence Based Medicine, 15(2), 40-41. https://doi.org/10.1136/ebm1034
Vancouver
Davis WA. Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA. Evidence Based Medicine. 2010;15(2):40-41. doi:10.1136/ebm1034
BibTeX
@article{Davis2010,
author = {Davis, Wendy A},
title = {Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA},
journal = {Evidence Based Medicine},
year = {2010},
volume = {15},
number = {2},
pages = {40--41},
doi = {10.1136/ebm1034}
}
EUVIMED